Positive Preclinical Data of the First “Off the Shelf,” GMP-Grade,
IL-2-Independent NK Cell Line Expressing the High-Affinity Fc-Receptor
to Augment Antibody Therapeutics
NantKwest Inc. (Nasdaq:NK), a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the unique
power of our immune system using natural killer (NK) cells to treat
cancer, infectious diseases and inflammatory diseases, today announced
that the company will be presenting an abstract at the upcoming American
Association of Cancer Research Annual Meeting (AACR).
The abstract will be presented on April 18, 2016 at the 107th Annual
Meeting of the American Association for Cancer Research in New Orleans,
Louisiana.
"NantKwest is rapidly advancing next generation, NK cell-based
immunotherapies that are designed to dramatically improve clinical
outcomes for cancer patients. We are pleased to have been invited to
present additional preclinical data associated with our high affinity
natural killer cell program, haNK, at the upcoming AACR meeting," said
Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest. "This latest
preclinical data further validates NantKwest’s unique approach to
harnessing the power of the innate immune system using natural killer
cells as therapeutic agents and also helps guide the design of clinical
trials for the haNK program and transition this program into human
clinical trials in the second half of 2016. These trials will be part of
the Cancer Moonshot 2020 initiative (www.Cancermoonshot2020.org)
to further the acceleration of combination immunotherapy with monoclonal
antibodies such as rituximab, trastuzumab, and daratumumab."
The presentation details are as follows:
Title: An 'off the shelf,' GMP-grade, IL-2-independent NK cell line
expressing the high-affinity Fc-receptor to augment antibody therapeutics
Presentation Time: Monday, April 18, 2016, 1:00 PM - 5:00 PM, Location:
Section 25, Poster Board Number: 14
Author: Laurent Boissel1, Hans Klingemann1, Kerry
Campbell2, Karen Nichols1, Frances Toneguzzo1,
Paula Marcus3, Brent Williams3, Armand Keating3,
Patrick Soon-Shiong4. 1NantKwest, Inc.,
Cambridge, MA; 2Fox Chase Cancer Center, Philadelphia,
PA; 3Princess Margaret Cancer Centre, Toronto, ON, Canada; 4NantKwest,
Inc., Culver City, CA
Abstract Summary
A GMP-grade plasmid-transfected variant of NK-92 expressing the
high-affinity CD16 receptor was developed utilizing a novel transfection
vector containing the erIL-2 gene, enabling the resulting haNK cells to
grow independently of IL-2. Using limiting dilution, clones having
identical surface molecule expression to the parent cell line were
generated and shown to have long-term expression of CD16. The haNK cells
displayed high ADCC in combination with rituximab, trastuzumab, and
daratumumab against target cell lines that were not killed by the
parental NK-92 cells. In summary, haNK cells are a potent and versatile
platform for cellular immunotherapy, and clinical trials of these novel
"off the shelf" high-affinity NK cells are scheduled for 2016.
About NantKwest Inc.
NantKwest (Nasdaq:NK) is a next generation, clinical-stage immunotherapy
company focused on harnessing the unique power of our immune system
using natural killer (NK) cells to treat cancer, infectious diseases and
inflammatory diseases. NK cells are the body’s first line of defense due
to the innate ability of NK cells to rapidly identify and destroy cells
under stress, such as cancer or virally-infected cells.
NantKwest’s unique NK cell-based platform, with the capacity to grow
active killer cells as a biological cancer therapy, has been designed to
induce cell death against cancer or infected cells by three different
modes of action: (1) Direct killing using activated NK cells (aNK) that
release toxic granules directly into the cell through cell to cell
contact, (2) Antibody-mediated killing using haNKs, which are NK cells
engineered to incorporate a high affinity receptor that binds to an
administered antibody, enhancing the cancer cell killing effect of that
antibody, and (3) Targeted activated killing using taNKs, which are NK
cells engineered to incorporate chimeric antigen receptors (CARs) to
target tumor-specific antigens found on the surface of cancer cells.
NantKwest’s aNK, haNK and taNK platform addresses certain limitations of
T cell therapies including the reduction of risk of serious “cytokine
storms” reported after T cell therapy. As an “off the shelf” therapy,
NantKwest’s NK cells do not rely on a patient’s own often compromised
immune system. In Phase 1 clinical trials in patients with late stage
cancer, NantKwest’s NK cells have been successfully administered as an
outpatient infusion therapy without any reported severe side effects,
even at doses of 10 billion cells.
By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs that include a Phase 2 trial
for a rare form of melanoma and the planned initiation of a clinical
trial of NK cells targeted to breast cancer, NantKwest believes it is
uniquely positioned to be the premier immunotherapy company and to
transform medicine by delivering living drugs in a bag and bringing
novel NK cell-based therapies to routine clinical care.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20160415005974r1&sid=ntxv4&distro=nx&lang=en)
View source version on businesswire.com: http://www.businesswire.com/news/home/20160415005974/en/
Copyright Business Wire 2016